Claims for Patent: 10,894,028

Summary for Patent: 10,894,028

Title:	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Abstract:	In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
Inventor(s):	Soni; Paresh (Mystic, CT)
Assignee:	Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:	16/775,521
Patent Claims:	1. A method of reducing risk of myocardial infarction in a subject, the method comprising administering to said subject about 4 g of ethyl icosapentate per day for a period effective to reduce risk of myocardial infarction in the subject wherein, the subject has diabetes and at least one additional risk factor for cardiovascular disease. 2. The method of claim 1, wherein the subject has a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL and a fasting baseline LDL-C level of about 40 mg/dL to about 100 mg/dL. 3. The method of claim 1, wherein the ethyl icosapentate is present in a pharmaceutical composition and the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition. 4. The method of claim 1, wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules. 5. The method of claim 1, wherein said period ends at least 2 years after initial administration of the ethyl icosapentate to the subject. 6. The method of claim 1, wherein the subject is on statin therapy. 7. The method of claim 1, wherein the subject has a triglyceride level of at least 135 mg/dL. 8. The method of claim 1, wherein the subject has a triglyceride level of at least 135 mg/dL and is on statin therapy. 9. The method of claim 1, wherein the at least one additional risk factor is selected from hypertension, smoking, retinopathy and albuminuria. 10. The method of claim 1, wherein the subject has at least two additional risk factors for cardiovascular disease.